Kisqali Patient Counseling Information

Advise the patient to read the Patient Information section.
QT Prolongation: Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately for signs or symptoms of QT prolongation (see Precautions).
Hepatobiliary Toxicity: Inform patients of the signs and symptoms of hepatobiliary toxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatobiliary toxicity (see Precautions).
Neutropenia: Advise patients of the possibility of developing neutropenia and to immediately contact their healthcare provider should they develop a fever, particularly in association with any suggestion of infection (see Precautions).
Embryo-Fetal Toxicity: Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during KISQALI therapy and for at least 3 weeks after the last dose. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during treatment with KISQALI (see Precautions and Use in Pregnancy & Lactation).
Lactation: Advise lactating women not to breastfeed during treatment with KISQALI and for at least 3 weeks after the last dose (see Use in Pregnancy & Lactation).
Drug Interactions: Inform patients to avoid grapefruit or grapefruit juice while taking KISQALI (see Interactions).
Inform patients to avoid strong CYP3A inhibitors, strong CYP3A inducers, and drugs known to prolong the QT interval (see Interactions).
Dosing: Instruct patients to take the doses of KISQALI at approximately the same time every day and to swallow whole (do not chew, crush, or split them prior to swallowing) (see Dosage & Administration).
If patient vomits or misses a dose, advise the patient to take the next prescribed dose at the usual time (see Dosage & Administration).
Advise the patient that KISQALI may be taken with or without food (see Dosage & Administration).